Roy Baynes, MB.Bch., M.Med., Ph.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Baynes currently serves as Chief Medical Officer at Eikon Therapeutics, Inc. Dr. Baynes previously served as Chief Medical Officer at Merck & Co., where he was responsible for the development of the entire clinical portfolio in Merck Research Laboratories, and was the architect of the development strategy for dozens of important new medicines including pembrolizumab, a humanized monoclonal antibody used in cancer immunotherapy that treats some 17 different tumor types as well as two histology agnostic indications. Earlier in his career, Dr. Baynes served as Vice President of Global Development and head of the hematology/oncology development team at Amgen, Inc., as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., and as Professor of Medicine at University of Kansas Medical Center and Wayne State University in Detroit as well as holding the Charles Martin endowed chair of Cancer Research at Wayne State University. Dr. Baynes holds an MB.BCh. (Bachelor of Medicine and Surgery), an M.Med. (specialist registration in Internal Medicine), and a Ph.D. from the University of Witwatersrand.
Ronald Levy, M.D.
Ronald Levy, M.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. He is also the Associate Director of Translational Science for the Stanford Cancer Institute. For more than 25 years, Dr. Levy’s research has focused on monoclonal antibodies and the study of malignant lymphoma, currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab, the first FDA-approved antibody for the treatment of lymphoma. Dr. Levy holds an A.B. in Biochemistry from Harvard University and an M.D. from Stanford University.
Seema P. Rogers, M.S.
Seema P. Rogers, M.S., has served as Head of Clinical Operations of Nurix since August 2019, first as Executive Director from August 2019 to June 2021 and currently as Vice President since June 2021. Ms. Rogers has over 20 years of experience in clinical drug development, primarily in oncology. Before joining Nurix, Ms. Rogers served in a consulting capacity at IGM Biosciences, Stemcentrx (acquired by AbbVie) and Reflexion Medical. Prior to consulting, she worked at FivePrime Therapeutics where she built the company’s clinical operations organization, was responsible for defining operational strategy and managed the development of concurrent assets in oncology. Early in her career, Ms. Rogers served in positions of increasing responsibility at organizations including Cell Genesys, Geron, Genentech and Stanford University, where she managed global clinical trials in all phases of development. Ms. Rogers holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.S. from The Johns Hopkins University.
Marine Champsaur, Ph.D.
Marine Champsaur, Ph.D., has served as Vice President and Head of Medical Affairs since August 2022. Prior to joining Nurix, Dr. Champsaur provided scientific strategy and communications consulting services to early-stage biotech companies across a range of treatment modalities spanning the autoimmune and inflammatory disease, vaccine, and oncology space. Before that, Dr. Champsaur played a pivotal role in building the medical affairs function at Dermira, Inc., where she led the medical strategy and communications team. Early in her career, she held roles of increasing responsibility at UCB Pharma within immunology global medical affairs. Dr. Champsaur holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and a Ph.D. in Immunology from the University of California, San Francisco.
Joseph D. Robinson
Joseph D. Robinson has served as Vice President, Facilities Operations at Nurix since July 2023. Mr. Robinson has been responsible for developing the facilities, real estate, lab services and operations functions at Nurix since he joined the company in January 2016. Prior to Nurix, Mr. Robinson served in positions of increasing responsibility developing and growing administrative and operational functions for early-stage companies, including Presidio Pharmaceuticals, a developer of anti-viral therapeutics, and VaxGen, a vaccine company. Mr. Robinson began his career at the Conant Medical Group. Mr. Robinson studied Communications at San Francisco State University and Management at St. Mary’s College of California.
John Kuriyan, Ph.D.
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
Michael Rapé, Ph.D.
Michael Rapé, Ph.D., is a leader in the biology of ubiquitin-dependent cell cycle progression and carcinogenesis. He is a Howard Hughes Investigator and a Professor of Cell and Developmental Biology at the University of California, Berkeley. He started his own lab at the University of California, Berkeley in the fall of 2006, where he has developed novel screening tools to identify the ubiquitylation enzymes that are important for cell division and differentiation and pair them with the proteins they target. Prior to that, he completed his postdoctoral research at Harvard Medical School in the lab of Marc Kirschner. In recognition of his creativity and productivity, Dr. Rapé was named a Pew Scholar and received the NIH Director’s New Innovator Award in 2007. He has also won prestigious fellowships from the Human Frontier Science Program and the European Molecular Biology Organization. Dr. Rapé studied Biochemistry at the University of Bayreuth in Germany and received his Ph.D. at the MPI in Martinsried, Germany in the lab of Stefan Jentsch.
Eren Demirhan, Ph.D.
Eren Demirhan, Ph.D., has served as Vice President and Head of Biometrics at Nurix since March 2021, leading the Company’s Biostatistics and Clinical Data Science efforts. Dr. Demirhan brings over 17 years of experience in drug pharmaceuticals and biotechnology, championing data-driven drug development ideology and implementation. Prior to joining Nurix, Dr. Demirhan served in a variety of roles at Allogene Therapeutics, Medivation, Onyx Pharmaceuticals, Novartis, Biogen, and GSK. Dr. Demirhan holds a B.A. in Statistics from Middle East Technical University, a Ph.D. in Statistics from North Carolina State University and an M.B.A from Kenan Flagler Business School, University of North Carolina – Chapel Hill.
Elizabeth Bosch, Ph.D.
Elizabeth Bosch, Ph.D., has served as Vice President, Alliance and Program Management at Nurix since January 2023 and served as the company’s Head of Alliance Management and Research Program Management from June 2018 through December 2022. Prior to joining Nurix, she worked at Five Prime Therapeutics, Inc., Incyte Corporation and Sentinel Biosciences, Inc. Dr. Bosch earned an M.S. and Ph.D. from the University of California, Los Angeles and completed her postdoctoral work at the Cell Signaling Dept, DNAX/Schering Plough Biopharma and the Jules Stein Eye Institute at UCLA.
Bev Benson, Ph.D.
Bev Benson, Ph.D., has served as Vice President and Head of Clinical Science at Nurix since January 2022. Dr. Benson has over 22 years of experience in drug development across numerous indications and has worked on five drugs that have received FDA approval. During her career, she has worked as a Clinical Scientist serving in positions of increasing responsibility at Amgen, Jazz Pharmaceuticals, BeiGene, CytomX Therapeutics and most recently at Principia Biopharma. Dr. Benson holds a B.S. in Microbiology from the University of Oklahoma and a Ph.D. in Pharmacology & Toxicology from the University of Kansas, and she completed her postdoctoral fellowship at the Huntsman Cancer Institute at the University of Utah.
'